News and Announcements
Bamboo launch Closed Beta for a select 200 Australian residents
- Published October 21, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Bamboo’s Closed Beta is in high demand and is finally launching, with limited early access spots.
- There are over 5000 people on the waiting list and only 200 spots available.
- Bamboo Core AG’s first project, Bamboo, is a fast, easy and safe way to purchase cryptocurrencies, utilising microsavings and proof-of-solvency.
The wait is over for the much anticipated launch of Bamboo’s Closed Beta.
Bamboo’s Closed Beta is now launching for a select 200 Australian residents who will have the opportunity to experience the Bamboo platform before anyone else.
There are over 5000 people on the waiting list and only 200 spots available in the beta.
Selected residents will have the opportunity to provide feedback before the rest of the world.
The Closed Beta is to be launched in Australia, Switzerland and the United States.
About Bamboo
Bamboo Core AG’s first project, Bamboo, is a fast, easy and safe way to purchase cryptocurrencies, utilising microsavings and proof-of-solvency. Blockchain’s biggest advocates and innovators may not yet have entered the market and we want to encourage them to do so. With Bamboo, this is what we are determined to achieve. Helping users invest today’s change into tomorrow.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
